PT - JOURNAL ARTICLE AU - Coryell, Michael P. AU - Iakiviak, Mikhail AU - Pereira, Nicole AU - Murugkar, Pallavi P. AU - Rippe, Jason AU - Williams, David B. AU - Hastie, Jessica L. AU - Sava, Rosa L. AU - Lien, Christopher Z. AU - Wang, Tony T. AU - Muller, William J. AU - Fischbach, Michael A. AU - Carlson, Paul E. TI - Validation and testing of a method for detection of SARS-CoV-2 RNA in healthy human stool AID - 10.1101/2020.11.09.20228601 DP - 2020 Jan 01 TA - medRxiv PG - 2020.11.09.20228601 4099 - http://medrxiv.org/content/early/2020/11/12/2020.11.09.20228601.short 4100 - http://medrxiv.org/content/early/2020/11/12/2020.11.09.20228601.full AB - Background Fecal shedding of SARS-CoV-2 has raised concerns about transmission through fecal microbiota transplantation (FMT) procedures. While many tests have been authorized for diagnosis of COVID-19 using respiratory samples, no fully validated stool tests for detection of SARS-CoV-2 are currently available. We sought to adapt and validate an available test specifically for detection of SARS-CoV-2 in human stool.Methods Stool samples were spiked with inactivated SAR-CoV-2 virus for development and validation of the assay. A modified version of the CDC rRT-PCR SARS-CoV-2 test was used for detection of virus. Analytical sensitivity, assay reproducibility, and sample stability under a variety of storage conditions were assessed. We also performed the assay on stool samples collected from known COVID positive individuals.Findings The lower limit of detection (LoD) of the assay was found to be 3000 viral RNA copies per gram of original stool sample, with 100% detection across 20 replicates assessed at this concentration. Samples were relatively stable in all buffers tested at both 4°C and ambient temperature, with the exception of storage in STAR buffer at ambient temperature. Assay sensitivity was slightly diminished in low-copy-number samples after a single freeze-thaw cycle at −80°C. Thirty contrived SARS-CoV-2 samples were tested by a second laboratory and were correctly identified as positive or negative in at least one of two rounds of testing. Additionally, we detected SARS-CoV-2 RNA in the stool of known COVID-19 positive individuals using this method.Interpretation This is a sensitive, reproducible, and validated assay for detection of SARS-CoV-2 RNA in human stool with potential uses in FMT donor screening, sewage monitoring, and further research into the impact of fecal shedding on the epidemiology of this pandemic.Funding National Institute for Allergy and Infectious Diseases, NIH. Center for Biologics Evaluation and Research, FDA.Evidence before this study Since the onset of the COVID-19 pandemic, multiple studies have documented shedding of SARS-CoV-2 RNA in feces and considered the potential for fecal-oral transmission of this virus. This potential risk led to the U.S. Food and Drug Administration issuing a safety alert that contained the recommendation that no stool donated after December 1, 2019 be used for manufacture of Fecal Microbiota for Transplantation (FMT) products in the United States until such a time as sufficient screening procedures could be put in place to mitigate this risk.Added value of this study Here, we report the development and validation of an assay specifically meant for the detection of SARS-CoV-2 RNA in the stool of healthy individuals. While studies have reported detection of viral RNA in stool previously, this is the first publication of a validated assay designed for this purpose.Implications of all the available evidence The work presented here provides a validated SARS-CoV-2 stool assay with potential application to FMT donor screening protocols, sewage monitoring protocols, as well as research studies assessing the role of stool shedding and transmission on the epidemiology of COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by an Inter-Agency Agreement to PC between the National Institutes for Health and Food and Drug Administration (AAI17016-001-00001) and the Intramural Research Program of the Center for Biologics Evaluation and Research, Food and Drug Administration. This project was supported in part by an appointment to the Research Fellowship Program at the OVRR/CBER, U.S. Food and Drug Administration, administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and FDA.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Collection of clinical samples was done under IRB at Northwestern University.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated for this study are presented in the manuscript.